Literature DB >> 34244313

NF-κB-dependent IRF1 activation programs cDC1 dendritic cells to drive antitumor immunity.

Ghita Ghislat1, Ammar S Cheema1, Elodie Baudoin1, Christophe Verthuy1, Pedro J Ballester2, Karine Crozat1, Noudjoud Attaf1, Chuang Dong1, Pierre Milpied1, Bernard Malissen1, Nathalie Auphan-Anezin1, Thien P Vu Manh1, Marc Dalod1, Toby Lawrence3,4,5.   

Abstract

Conventional type 1 dendritic cells (cDC1s) are critical for antitumor immunity. They acquire antigens from dying tumor cells and cross-present them to CD8+ T cells, promoting the expansion of tumor-specific cytotoxic T cells. However, the signaling pathways that govern the antitumor functions of cDC1s in immunogenic tumors are poorly understood. Using single-cell transcriptomics to examine the molecular pathways regulating intratumoral cDC1 maturation, we found nuclear factor κB (NF-κB) and interferon (IFN) pathways to be highly enriched in a subset of functionally mature cDC1s. We identified an NF-κB-dependent and IFN-γ-regulated gene network in cDC1s, including cytokines and chemokines specialized in the recruitment and activation of cytotoxic T cells. By mapping the trajectory of intratumoral cDC1 maturation, we demonstrated the dynamic reprogramming of tumor-infiltrating cDC1s by NF-κB and IFN signaling pathways. This maturation process was perturbed by specific inactivation of either NF-κB or IFN regulatory factor 1 (IRF1) in cDC1s, resulting in impaired expression of IFN-γ-responsive genes and consequently a failure to efficiently recruit and activate antitumoral CD8+ T cells. Last, we demonstrate the relevance of these findings to patients with melanoma, showing that activation of the NF-κB/IRF1 axis in association with cDC1s is linked with improved clinical outcome. The NF-κB/IRF1 axis in cDC1s may therefore represent an important focal point for the development of new diagnostic and therapeutic approaches to improve cancer immunotherapy.
Copyright © 2021 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34244313     DOI: 10.1126/sciimmunol.abg3570

Source DB:  PubMed          Journal:  Sci Immunol        ISSN: 2470-9468


  3 in total

1.  Duhuo Jisheng Decoction inhibits the activity of osteoclasts in osteonecrosis of the femoral head via regulation of the RELA/AKT1 axis.

Authors:  Tao Xing; Yongqiang Zhao; Jun Zhao; Zhenxing Jiang; Yingshuan Zhang; Shenghua Li
Journal:  Am J Transl Res       Date:  2022-05-15       Impact factor: 3.940

Review 2.  Immunological Classification of Tumor Types and Advances in Precision Combination Immunotherapy.

Authors:  Xiufang Ren; Songyi Guo; Xiaojiao Guan; Ye Kang; Jiamei Liu; Xianghong Yang
Journal:  Front Immunol       Date:  2022-02-28       Impact factor: 7.561

3.  Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC.

Authors:  Robert Saddawi-Konefka; Aoife O'Farrell; Farhoud Faraji; Lauren Clubb; Michael M Allevato; Shawn M Jensen; Bryan S Yung; Zhiyong Wang; Victoria H Wu; Nana-Ama Anang; Riyam Al Msari; Shiruyeh Schokrpur; Ida Franiak Pietryga; Alfredo A Molinolo; Jill P Mesirov; Aaron B Simon; Bernard A Fox; Jack D Bui; Andrew Sharabi; Ezra E W Cohen; Joseph A Califano; J Silvio Gutkind
Journal:  Nat Commun       Date:  2022-07-25       Impact factor: 17.694

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.